The primary endpoint of the study measured the efficacy of NG2-73 in reducing time to onset of persistent sleep in a well established clinical model of transient insomnia in healthy adults.
In this multi-center, 369 subject study, NG2-73 was shown to significantly reduce time to onset of persistent sleep versus placebo at all doses tested.
The drug was also shown to be well-tolerated at all doses, with no drug-related serious adverse events or drug-related premature subject withdrawals.
“In studies to date, NG2-73 has been shown to be a safe and potent sleep agent that reduces sleep latency and increases total sleep time and sleep efficiency. The fast onset of action of this compound may serve to differentiate it from other sleep agents, providing an important treatment option for patients suffering from insomnia,” said principle investigator Dr Gary Zammit, clinical associate professor of psychology, Columbia University.